.Nature Medicine, Released online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) treatment of patients along with HER2+ sophisticated bosom cancer cells and also energetic or even dependable brain metastases presented steady intracranial task as well as wide spread efficacy of T-DXd.